Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
871
Zitationen
13
Autoren
2020
Jahr
Abstract
Achieving pCR following NAT is associated with significantly better EFS and OS, particularly for triple-negative and HER2<sup>+</sup> breast cancer. The similar outcomes with or without adjuvant chemotherapy in patients who attain pCR likely reflects tumor biology and systemic clearance of micrometastatic disease, highlighting the potential of escalation/deescalation strategies in the adjuvant setting based on neoadjuvant response.<i>See related commentary by Esserman, p. 2771</i>.
Ähnliche Arbeiten
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 · 15.699 Zit.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 · 13.213 Zit.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · 11.469 Zit.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 · 10.905 Zit.
Gene expression profiling predicts clinical outcome of breast cancer
2002 · 9.587 Zit.